Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120
- PMID: 7687306
- PMCID: PMC237881
- DOI: 10.1128/JVI.67.8.4932-4944.1993
Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120
Abstract
A number of linear and conformation-dependent neutralizing monoclonal antibodies (MAbs) have been mapped to the first and second variable (V1 and V2) domains of human immunodeficiency virus type 1 (HIV-1) gp120. The majority of these MAbs are as effective at neutralizing HIV-1 infectivity as MAbs to the V3 domain and the CD4 binding site. The linear MAbs bind to amino acid residues 162 to 171, and changes at residues 183/184 (PI/SG) and 191/192/193 (YSL/GSS) within the V2 domain abrogate the binding of the two conformation-dependent MAbs, 11/68b and CRA-4, respectively. Surprisingly, a change at residue 435 (Y/H or Y/S), in a region of gp120 near the CD4 binding site (M. Kowalski, J. Potz, L. Basiripour, T. Dorfman, W. C. Goh, E. Terwilliger, A. Dayton, C. Rosen, W. Haseltine, and J. Sodroski, Science 237:1351-1355, 1987; L. A. Lasky, G. M. Nakamura, D. H. Smith, C. Fennie, C. Shimasaki, E. Patzer, P. Berman, T. Gregory, and D. Capon, Cell 50:975-985, 1987; and U. Olshevsky, E. Helseth, C. Furman, J. Li, W. Haseltine, and J. Sodroski, J. Virol. 64:5701-5707, 1990), abrogated gp120 recognition by both of the conformation-dependent MAbs. However, both MAbs 11/68b and CRA-4 were able to bind to HIV-1 V1V2 chimeric fusion proteins expressing the V1V2 domains in the absence of C4, suggesting that residues in C4 are not components of the epitopes but that amino acid changes in C4 may affect the structure of the V1V2 domains. This is consistent with the ability of soluble CD4 to block 11/68b and CRA-4 binding to both native cell surface-expressed gp120 and recombinant gp120 and suggests that the binding of the neutralizing MAbs to the virus occurs prior to receptor interaction. Since the reciprocal inhibition, i.e., antibody inhibition of CD4-gp120 binding, was not observed, the mechanism of neutralization is probably not a blockade of virus-receptor interaction. Finally, we demonstrate that linear sequences from the V2 region are immunogenic in HIV-1-infected individuals, suggesting that the primary neutralizing response may be directed to both V2 and V3 epitopes.
Similar articles
-
Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120: role of glycosylation in the correct folding of the V1/V2 domain.J Virol. 1995 Apr;69(4):2271-8. doi: 10.1128/JVI.69.4.2271-2278.1995. J Virol. 1995. PMID: 7533854 Free PMC article.
-
Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120.J Virol. 1994 Sep;68(9):5854-62. doi: 10.1128/JVI.68.9.5854-5862.1994. J Virol. 1994. PMID: 7520095 Free PMC article.
-
Identification and characterization of monoclonal antibodies specific for polymorphic antigenic determinants within the V2 region of the human immunodeficiency virus type 1 envelope glycoprotein.J Virol. 1995 Jan;69(1):222-30. doi: 10.1128/JVI.69.1.222-230.1995. J Virol. 1995. PMID: 7527084 Free PMC article.
-
Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1.J Virol. 1993 Oct;67(10):6179-91. doi: 10.1128/JVI.67.10.6179-6191.1993. J Virol. 1993. PMID: 7690420 Free PMC article.
-
A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.J Virol. 2003 Jun;77(12):6965-78. doi: 10.1128/jvi.77.12.6965-6978.2003. J Virol. 2003. PMID: 12768015 Free PMC article.
Cited by
-
Multiple pathways of escape from HIV broadly cross-neutralizing V2-dependent antibodies.J Virol. 2013 May;87(9):4882-94. doi: 10.1128/JVI.03424-12. Epub 2013 Feb 13. J Virol. 2013. PMID: 23408621 Free PMC article.
-
Systematic comparison of HIV-1 Envelope-specific IgG responses induced by different vaccination regimens: Can we steer IgG recognition towards regions of viral vulnerability?Front Immunol. 2023 Jan 9;13:1075606. doi: 10.3389/fimmu.2022.1075606. eCollection 2022. Front Immunol. 2023. PMID: 36741409 Free PMC article.
-
Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera.J Virol. 1995 Jan;69(1):39-48. doi: 10.1128/JVI.69.1.39-48.1995. J Virol. 1995. PMID: 7983734 Free PMC article.
-
Length polymorphism within the second variable region of the human immunodeficiency virus type 1 envelope glycoprotein affects accessibility of the receptor binding site.J Virol. 1997 Jan;71(1):759-65. doi: 10.1128/JVI.71.1.759-765.1997. J Virol. 1997. PMID: 8985413 Free PMC article.
-
Study of the dynamics of neutralization escape mutants in a chimpanzee naturally infected with the simian immunodeficiency virus SIVcpz-ant.J Virol. 1997 Mar;71(3):2320-30. doi: 10.1128/JVI.71.3.2320-2330.1997. J Virol. 1997. PMID: 9032368 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous